HDAC4 and cancer: Additional studies document that when tasquinimod binds to the open conformation of HDAC4, it prevents binding of N-CoR/HDAC3 thus preventing client protein deacetylation in both hypoxic cancer cells and their endothelial support cells needed for survival signaling and angiogenesis [12].